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Abstract: Lost production can be due to individuals’ time lost to work (absenteeism), as well 
as their time at work with reduced productivity because of ill health (presenteeism). A sound 
methodological framework for the assessment of presenteeism remains to be established but 
given its significance, ignoring it would lead to severe underestimations, eg, in cost-of-illness 
studies. The objective of this study was to assess the empirical significance of absenteeism 
and presenteeism in terms of production loss using the case of rheumatoid arthritis (RA). 
Selected modules from the Health and Labor Questionnaire were applied in a cross-sectional 
study of 3,704 patients with RA. The costs of absenteeism and presenteeism were estimated 
using the Human Capital approach, and the impact of including multipliers adjusting for the 
productivity effect of a workers’ absence or impaired presenteeism on societal productivity 
was demonstrated. RA-related absenteeism over the last 14 days was 22.31 hours (standard 
deviation [SD], 26.51) with a resulting cost of €473 (SD, 575) and €762 (SD, 926) depending 
on whether a multiplier was included. Presenteeism was found to affect 7.98 (SD, 3.24) 
working days over the last 14 days with a resulting cost of €168 (SD, 203) and €203 (SD, 245), 
again depending on whether a multiplier was included. Overall, this article demonstrates that 
the value of lost production due to RA could be subject to an almost factor 2 increase if 
productivity effects of presenteeism and general multipliers are included.
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Introduction
Rheumatoid arthritis (RA) is the most common inflammatory arthritis in adults affecting 
up to 1% of the population worldwide. It is a highly disabling disease that has been 
found to significantly depress health-related quality of life not only compared with 
the normal population but also with other musculoskeletal diseases, eg, symptomatic 
osteoarthritis, low back pain, and soft tissue disorders.1,2 The economic burden of RA 
to society has been estimated at €45.3 billion in Europe and €41.6 billion in the United 
States due to both direct health care costs and indirect costs of functional disability.3 
In fact, about every second patient with RA can expect work disability within 10 years 
after disease onset, and thus, the costs of societal production loss are assumed to account 
for more than 50% of the total costs of the disease.4 Some of the more recent estimates 
of the value of lost production range from €5,076 to €10,900 per patient per year when 
using the Human Capital approach for evaluating production losses.5–11
The value of lost production can be defined as the value of lost productivity and/or 
the costs incurred to maintain societal productivity as a result of a worker’s ill health.12 
As such at least two scenarios lead to productivity losses: short-term or   long-term ClinicoEconomics and Outcomes Research 2010:2 submit your manuscript | www.dovepress.com
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sickness leave (absenteeism) and reduced efficiency while 
working (impaired presenteeism, generally termed just pre-
senteeism). In a systematic literature review from 2006, it 
was concluded that none of the identified studies assessing 
the value of lost production in RA had included the costs of 
presenteeism.13 Since then, however, a Canadian study across 
383 employed individuals has been reported; productivity 
loss was measured in dimensions of RA-related absences, 
reduced performance, decreased working hours, job change, 
and work disability, and included in a model of the overall 
cost of production loss.14 Interestingly, presenteeism was 
found to account for 41% of total costs, whereas decreased 
work hours and absenteeism accounted for only 12% and 
10%, respectively. These findings indicate that the current 
estimates of the RA-related costs of production loss are 
severely underestimated.
The reason for presenteeism generally not being included 
could be methodological challenges of measuring on-the-job 
efficiency.15,16 Not only is the frequency and the   duration 
of reduced productivity required to quantify events of 
presenteeism, disease-related deviations from the normal 
level of efficiency (optimally in terms of both quality and 
quantity of work) must be assessed too.17 This often means 
that   asking workers is not sufficient for valid observations 
as most workers’ productivity is interrelated with colleague 
workers’ productivity due to, eg, team production and 
time sensitivity of individual outputs. Such effects have 
been examined in relation to absenteeism in which the 
health-related impact on productivity was found to be up 
to multiple times the wage of the absent worker, depending 
on the type of job   characteristics.18 This means that simply 
  measuring number of days lost to work and multiplying it 
by the daily wage rate would underestimate the value of the 
true   productivity effect.
A recent contribution to the question of how to mea-
sure the effects of presenteeism on productivity was 
reported by Pauly et al19 who surveyed more than 800 
employers across 12 industries and various job types. The 
idea of their work was not only to quantify the extent of 
impaired   presenteeism for individual workers but also 
to estimate the effect of such to corporate productivity. 
For that purpose, the authors commented that managers 
are essentially and intrinsically the most appropriate 
respondents. The first parameter was measured in terms 
of percentage of fewer hours a worker provides in case 
of acute and chronic illness and found to an average 29% 
and 27%, respectively. The second parameter, a multiplier 
expressing the impact to corporate   productivity of a unit 
of presenteeism, was estimated between 1.12 and 1.71 for 
acute conditions and between 1.21 and 2.00 for chronic 
conditions, depending on the econometric model applied. 
The overall result of these estimations was expressed 
as the effect of presenteeism on the output of a whole 
department as a percentage of the wage of the worker 
suffering ill health.
The objective of this study was to assess the   empirical 
significance of both absenteeism and presenteeism as sources 
of lost production using the case of rheumatoid arthritis. 
In addition to being one of the first studies in RA to have 
included presenteeism as a source of production loss, the 
novelty of the present contribution is the adaptation of multi-
pliers of productivity effects from the recent literature, which 
are used to weigh original, patient-reported observations. The 
primary analysis of this study is restricted to patients who are 
active at the labor market as nonemployed patients obviously 
cannot contribute to on-the-job production loss. A secondary 
analysis then extends the study sample also to include patients 
who are inactive at the labor market to demonstrate the 
potential impact of including presenteeism on estimates of 
the societal value of production loss. The secondary analysis 
compares four approaches that are based on the Human 
Capital approach for valuation: with and without including 
presenteeism and with and without adapting multipliers to 
account for the fact that productivity effects of a worker’s 
absence or presenteeism generally leads to a production loss, 
which is larger than the gross wage of that worker.
Method
Patients and study design
This study was part of a nationally representative cross-
sectional study examining the effects of biological and 
other treatments in RA.20,21 The study was undertaken from 
June 2006 to July 2007 at 11 hospital-based rheumatologic 
clinics. All patients with an RA diagnosis as defined by the 
American College of Rheumatology 1987 criteria22 were 
eligible for inclusion. Clinical data were recorded by physi-
cians and registered in the nationwide DANBIO registry that 
monitors medical treatment of RA patients.23
Patients’ self-reported ability to participate at the labor 
market was assessed using selected modules of the Health 
and Labor Questionnaire (HLQ).24 Module 1 was applied to 
assess patients’ absence from paid work, and the descriptive 
part of Module 2 was applied to assess reduced productivity 
at paid work. Both modules ask the respondent about the ClinicoEconomics and Outcomes Research 2010:2 submit your manuscript | www.dovepress.com
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compensation equivalent of the reduced productivity within 
the last 14 days.
Primary parameters
The primary parameters were 14-day prevalence of 
  absenteeism (in hours) and presenteeism (yes/no). The 
  number of hours of absenteeism was calculated from the 
patient-reported number of days (one day assumed to be 
equivalent to 7.4 hours) and half days (assumed to be 
equivalent to 3.7 hours) of reduced working time, sick leave 
due to RA, or sick leave due to other health problems. The 
prevalence of impaired presenteeism was reported on a 
Likert scale of “never,” “sometimes,” “often,” and “always” 
across six dimensions of work: concentration, pace of 
work, need to be alone, ability to make decisions, delays 
in work progress, and ability to take over colleagues’ work. 
Responses in   presenteeism were dichotomized by collapsing 
“sometimes,” “often,” and “always” as an expression of pre-
senteeism, whereas “never” expressed no presenteeism.
Valuation of parameters
The cost of absenteeism was estimated by the conventional 
approach of using workers’ time cost to approximate the value 
of their productive input. National average age-matched and 
gender-matched gross salaries were converted to a cost per 
hour (annual estimate/12 months/160.33 hours per month), 
which was multiplied by the hours observed. The cost was 
estimated with and without the inclusion of a multiplier of 
1.61, which was adapted from Nicholson et al18 who defines 
the multiplier as the cost to (societal)   production of an 
absence as a proportion of the absent worker’s daily wage.
The cost of presenteeism was based on two   assumptions 
due  to  the  format  of  observations  (proportion  of 
  respondents affected rather than exact amount of hours). 
First,   presenteeism was assumed to impact productivity 
if a respondent reported problems in at least three of the 
six dimensions. Second, the magnitude of productivity 
effects was adapted from the study of Pauly et al19 who 
concludes an average impact of presenteeism on pro-
ductivity of 0.27 for chronic health problems. Based on 
these assumptions, the value of production loss caused 
by presenteeism was calculated as events of presentee-
ism per half day of work, multiplied by national average 
age-matched and gender-matched gross salaries. Again, 
the cost was estimated with and without a multiplier; the 
estimate of 1.21 (applicable for chronic conditions) was 
adapted from Pauly et al.19
For the estimation of an annual value of production loss 
due to RA, four variants of the Human Capital approach 
was applied: basing estimates strictly on absenteeism (as is 
  generally the case in the clinical literature), basing estimates 
on both absenteeism and presenteeism, and combining each 
of these with the inclusion of multipliers. Gross salaries 
approximated the value of time of patients in paid employ-
ment and patients on sick leave. Housewives’ and students’ 
time were valued using net salaries (their opportunity cost for 
deciding not to be in paid employment). It should be noted 
that this represents a secondary analysis for the purpose of 
examining the impact of a refined approach only (multiplier 
approach including also presenteeism) as it is based on the 
additional assumption that observations of 14-day prevalence 
can be extrapolated to a whole year.
All monetary values are in 2007-EUR.
Sensitivity analysis
This study was explorative in assessing the impact of   different 
approaches for valuing productivity loss, rather than   providing 
empirical estimates for adaptation in, eg, models of the costs 
of RA, and for that reason comprehensive sensitivity analysis 
was inappropriate. Sensitivity analysis was   conducted for the 
parameter of presenteeism costs. In particular, the asumptions 
made to convert observed events of presenteeism per half day 
into a total number of hours and then into a total cost were 
tested. The wage rate used for valuation was kept constant in 
the sensitivity analysis. Two scenarios were tested. First, as 
the base-case scenario was fairly conservative in accepting 
on-the-job impairments only if observed in at least three of six 
dimensions of the presenteeism module, the impact of moving 
the cutpoint to impairments having effect if reported in only one 
dimension was tested. Second, as the base case did not allow the 
impact of presenteeism to vary in severity, the impact of grading 
it according to the number of dimensions reported was tested. 
This scenario included two subanalyses: one where the impact 
was allowed to vary from zero to a maximum, which is equal 
to the one adapted from Pauly et al19 (productivity deduction 
of 0.05 for every dimension affected) and another where the 
impact was allowed to vary from 0% to 200% (a productivity 
deduction of 0.10 for every dimension affected).
Statistical analysis
All parameters were reported as arithmetic means with standard 
deviations (SD) or as simple frequencies and percentages. The 
relation between absenteeism and presenteeism was examined 
using logistic regression and reported as odds ratios with ClinicoEconomics and Outcomes Research 2010:2 submit your manuscript | www.dovepress.com
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  confidence intervals (CI). A significance level of 0.05 was 
used, and all analysis was conducted in STATA version 11 
(StataCorp, College Station, TX).
Ethical considerations
All patients were informed that participation was voluntary and 
independent of the provision of treatment modalities. Participa-
tion was accepted by filling in questionnaires. The study was 
approved by the Data Protection Agency whereas, according to 
Danish law, no ethical approval was needed for this study.
Results
Of the 3,704 patients who received the HLQ questionnaire, 
1,900 (51%) responded. The response was   significantly 
  different between employed and nonemployed patients as 1,049 
(72%) in paid employment responded to the   questionnaire, 
whereas only 851 (38%) not in paid   employment responded. 
Accordingly, respondents were significantly younger and more 
likely to have college education than nonrespondents. Among 
those in paid work, which was the sample for the primary 
analysis, item responses (the extent to which individual items 
of the questionnaire were filled in by respondents; in the present 
context defined by at least one response in   respective modules of 
the HLQ) were 945 (86%) in the module   relating to absenteeism 
and 969 (88%) in the module relating to presenteeism.
Table 1 lists characteristics of the surveyed sample and 
the subgroup of patients in paid employment. For the latter 
group, the mean age was 49.94 (SD, 11.33) years and 74% 
were females. The impact of disease on respondents’ daily 
lives was reflected in a Health Assessment Questionnaire 
(HAQ) score of 0.38 (SD, 0.48) and in a health-related 
quality of life (EQ-5D) score of 0.75 (SD, 0.15). The current 
occupational status for patients in paid employment could be 
classified as 87% currently working, 7% on sick leave, and 
6% were not classifiable.
Absenteeism and presenteeism
The average RA-related absenteeism over the last 14 days 
was 22.31 (SD, 26.51) hours of which sick leave accounted 
for 3.67 (16.06) hours and the remainder represented reduced 
working hours (see Table 2).
Presenteeism was reported over six dimensions: 43.23% 
reported problems with concentration at work, 56.77% 
reported problems with the pace of work, 36.24% reported 
need to be alone during working time, 24.43% reported 
  problems with making decisions, 47.59% reported that their 
RA caused delays in work progress, and 36.26% reported to 
be less able to take over colleagues work (see Table 3).
It was noted that RA patients with an event of   absenteeism 
are at higher risk of also experiencing impairments on the job. 
Among the 126 patients who responded to the   presenteeism 
module of the questionnaire and who had at least one event of 
absenteeism, 113 (90%) also reported presenteeism (defined 
as problems in any of the six dimensions). This was assessed 
using logistic regression, which estimated the odds ratio 
for presenteeism given all-cause absenteeism at 4.13 (95% 
CI: 2.28–7.48) and the corresponding ratio for presenteeism 
given RA-related absenteeism at 15.29 (95% CI: 3.72–62.86).
The value of reduced productivity
The total cost of RA-related absenteeism was estimated at 
€473 (SD, 575) and €762 (SD, 926) for a 14-day period, 
Table 1 Baseline characteristics of the whole-study population of patients with rheumatoid arthritis (N = 3,704) and the subgroup of 
patients in paid employment (N = 1,455)
Whole-study  
population
Response, n Subgroup in paid  
employment
Response, n
Age, mean (SD) 60.63 (13.92) 3,703 49.94 (11.33) 1,455
Female, n (%) 2,780 (75) 3,704 1,081 (74) 1,455
HAQ score 2,407 961
  mean (SD) 0.73 (0.71) 0.48 (0.53)
  median (min; max) 0.50 (0.00; 3.00) 0.25 (0.00; 2.85)
EQ-5D score, mean (SD) 0.72 (0.17) 2,679 0.75 (0.15) 1,044
Current ability to work, n (%) 3,061 1,049
  Working full or part-time 957 (31) 916 (87)
  On sick leave 126 (4) 75 (7)
  On early retirement 717 (24) 0 (0)
  On pension 947 (31) 0 (0)
  Other 314 (10) 58 (6)
Abbreviations: SD, standard deviation; HAQ, Health Assessment Questionnaire; EQ-5D, EuroQol 5-dimensions.ClinicoEconomics and Outcomes Research 2010:2 submit your manuscript | www.dovepress.com
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depending on whether a multiplier was included. As 
the multiplier was a fixed parameter adapted from the 
literature of 1.61, the multiplier-based estimate is exactly 
161% of the conventional. Table 2 further lists the total cost 
of all-cause absenteeism, which was found to be €520 (SD, 
606) and €837 (SD, 976), again depending on whether a 
multiplier was included.
The costs of presenteeism were based on an average 
  number of working days (within the 14-day period) of 
7.98 (SD, 3.24) per patient and, in the base-case analysis, 
a   definition of presenteeism affecting productivity only if 
reported in at least three of the six dimensions (see Table 3). 
Thus, 430 patients (44%) reporting presenteeism in zero, 
one, or two dimensions did not contribute to the cost of 
presenteeism in the base case, which was estimated at 
€168 (SD, 203) and €203 (SD, 245), again depending on 
whether a   multiplier (of 1.21) was included. Sensitivity 
analysis moving the cutpoint from at least three dimen-
sions to instead at least one dimension resulted in a cost 
increase to €193 (SD, 160) for the estimate not including 
the multiplier. Furthermore, the impact of instead allow-
ing the severity of presenteeism to vary for the number of 
dimensions included was tested. A conservative scenario 
allowing the impact to vary from 0% to 30% reduced 
productivity as a percentage of the affected worker’s 
wage lead to a reduced cost of €117 (SD, 129), whereas a 
more extreme scenario of allowing the impact to vary to a 
doubled maximum lead to an increased cost of €233 (SD, 
257). As such, the impact of presenteeism is inherently 
subject to uncertainty, but it should be clear that at the 
same time it remains significant.
The value of lost production per year 
due to rheumatoid arthritis
As a supplement to the primary analysis and for comparison 
purposes, the sample of individuals in paid employment was 
extended to all patients (n = 3,704) for an overall estimate of 
the annual value of production loss due to RA. The impact of, 
first, including presenteeism as a source of production loss 
and, next, including multipliers to account for the effect of 
one worker’s productivity on societal production is presented 
in Table 4. The purely absenteeism-based, conventional 
estimate amounted to €14,920 (SD, 18,585), and the more 
comprehensive estimate, including both absenteeism-related 
and presenteeism-related productivity effects, as well as 
multipliers, amounted to €25,766 (SD, 29,776), which is an 
almost factor 2 increase.
Table 2 Absenteeism-related production loss in 942 working patients with RA: observed 14-day prevalence and the estimated value 
of production loss based on the Human Capital approach
Absenteeism in hours (SD) Production loss in 2007-EUR (SD)
Conventional approach Multiplier approach
Reduced working time 18.64 (22.90) 394 (494) 634 (795)
Sick-leave due to RA 3.67 (16.06) 79 (351) 128 (566)
Total RA-related absenteeism 22.31 (26.51) 473 (575) 762 (926)
Sick leave not related to RA 2.16 (11.04) 46 (241) 75 (388)
Total all-cause absenteeism 24.47 (27.83) 520 (606) 837 (976)
Note: The estimates of production loss represent (1) the conventional approach of using the workers’ gross wage (age-matched and gender-matched national averages 
were used) as an approximation for the value of the output generated by a worker and (2) the conventional approach with the addition of adapting a multiplier of 1.61 from 
Nicholson et al18 due to the cost of an absence often being larger than the absent worker’s daily wage because absence generally affects colleague workers productivity and 
a replacement worker might not be readily available.
Abbreviations: RA, rheumatoid arthritis; SD, standard deviation.
Table 3 Presenteeism-related production loss in 872 working 
patients with rheumatoid arthritis: observed 14-day prevalence 
and the estimated value of production loss based on the Human 
Capital approach
Dimension of presenteeism Patients reporting   
presenteeism, %
Problems with concentration at work 43.23
Problems with the pace of work 56.77
Need to be alone during working time 36.24
Problems with making decisions 24.43
Experience delays in work progress 47.59
Less able to take over colleague’s work 36.26
Summary estimates per patient Mean (SD)
No. of dimensions reported 2.42 (2.18)
No. of working days reported 7.98 (3.24)
Production loss (2007-EUR)
  Conventional approach 168 (203)
  Multiplier approach 203 (245)
Note: The estimates of production loss are based on an average reduction in worker 
productivity of 0.27 if presenteeism is reported in 3 or more dimensions; the conventional 
approach estimate uses the workers’ gross wage (age-matched and gender-matched national 
averages were used) as an approximation for the value of the output generated by a worker, 
whereas the multiplier approach further includes a multiplier of 1.21 from Pauly et al19 due to 
presenteeism often affecting departmental productivity rather than just output per worker.   
Abbreviation: SD, standard deviation.ClinicoEconomics and Outcomes Research 2010:2 submit your manuscript | www.dovepress.com
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Discussion
This study assessed the 14-day prevalence of two main 
causes of reduced productivity: absenteeism (time lost from 
work) and presenteeism (on-the-job work limitations), in a 
large cohort of patients. The objective was to examine the 
role of presenteeism as a significant source of production 
loss as it is   generally not included in economic evaluations 
or cost-of-illness studies in RA. The analysis furthermore 
included a second   dimension of using multipliers to derive 
societal production effects from a single worker’s absence 
or   presenteeism, which is also not common practice in the 
applied literature. Overall, it was demonstrated that current 
estimates of the value of lost   production due to RA could be 
significantly underestimated, in that productivity effects of 
presenteeism and general multipliers are not included.
Only one Canadian study has previously reported an 
estimate of the costs of presenteeism in arthritis.14 Based on 
a different approach than the one presented here, the authors 
concluded that the cost of presenteeism accounts for 41% of 
the cost of production loss. This is an even higher estimate than 
that of the present work, which was about 36% (€168/€473). 
The difference between estimates could be due to differences 
in the   measurement and valuation procedure (eg, different 
wage rates between Canada and Denmark) among other 
explanations. As a gold standard for assessing the cost of 
presenteeism has not been established, one empirical best bet 
can be as good as another.
The primary strength of this work in terms of the 
  estimates of 14-day costs of absenteeism and presenteeism 
is the sample size of 3,704 patients. Examining effects that 
  manifests in employed patients only requires more patients 
than is typically included in a clinical trial. Most RA patients 
will not be in paid employment, and even among those in paid 
employment, high response rates can be difficult to achieve 
due to respondents’ reticence relating to ongoing claims for 
social benefits. Another strength is the adaptation of a fixed, 
but well-founded, weight of the effect of presenteeism on the 
productivity of a company rather than assuming that reduced 
productivity of one worker does not affect colleague workers. 
On the other hand, such adaptation of a fixed weight should 
be criticized for not being specific to the type of jobs held 
by patients with RA. Indeed, a first-best approach would 
be stochastic measurements, but as study units of patients are 
most often incapable of determining productivity of whole 
departments, it would require a study design including both 
patients and their managers as study units.
The response rate of only 51% could have lead to selection 
bias. In particular, as it appeared that nonresponders were 
significantly older and had more symptoms (higher HAQ 
score), the estimated average costs of absenteeism and 
presenteeism may have been underestimated, whereas the 
impact of selection bias to the significance of presenteeism 
relative to absenteeism is uncertain. Other potential bias 
include recall bias from the 14-day recall period used in the 
HLQ, as well as bias from the sampling procedure, ie, by 
sampling from a clinical database, only individuals with 
formally diagnosed RA are included.
The modules of the HLQ used for the present study have 
been validated as part of the original validation study for 
the instrument reported in 1996.24 The validation study was 
conducted in 995 individuals from the general population 
and in four disease-specific populations (migraine and 
three   orthopedic diseases) and included issues of feasibility 
(response rates, missing values rates, completion time) 
and validity. The validity of responses of absenteeism was 
assessed by comparing self-reported values with data from 
Table 4 Comparison of variations of the Human Capital approach for valuing production loss: the case of working and nonworking 
patients with rheumatoid arthritis
n Annual production  
loss 2007-EUR (SD)
Range (min; max)
Conventional approach
  Absenteeism-based alone 2,419 14,920 (18,585) (0; 58,155)
    Absenteeism and presenteeism-based 2,419 16,362 (18,555) (0; 59,971)
Multiplier approach
  Absenteeism-based alone 2,419 24,021 (29,922) (0; 93,629)
    Absenteeism-based and presenteeism-based 2,419 25,766 (29,776) (0; 93,833)
Note: Although a greater “n” could have been achieved for some rows (the ones requiring the least data), n was defined as the largest sample for which all 4 estimates 
could be calculated. The estimates of production loss represent (1) the conventional approach of using the workers’ gross wage (age-matched and gender-matched national 
averages were used) as an approximation for the value of the output generated by a worker and (2) the conventional approach with the addition of adapting a multiplier 
of 1.61 from Nicholson et al18 due to the cost of an absence often being larger than the absent worker’s daily wage because absence generally affects colleague workers’ 
productivity and a replacement for them might not be readily available.
Abbreviation: SD, standard deviation.ClinicoEconomics and Outcomes Research 2010:2 submit your manuscript | www.dovepress.com
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a central office of statistics, whereas for assessing validity of 
responses concerning presenteeism, the authors commented 
that there was no gold standard. For that reason they compared 
the HLQ approach, which asks for a compensation equivalent 
of the reduced productivity, with the Osterhaus technique,25 
which asks for a performance level and from that derives a 
productivity measure. An overall consensus was found.
In terms of the more explorative, methodological focus 
of the present study, the complexity of measuring on-the-job 
efficiency must be understood to determine   validity of 
  findings. The parameter of impaired presenteeism is a 
composite of at least three variables that must be assessed 
stochastically to estimate it: frequency, length, and efficiency. 
Frequency refers to the number of episodes of impaired 
presenteeism, which in the present study was assumed to be 
all working days (during the last 14 days) for respondents 
reporting work limitations. This is legitimized from to the 
wording of the questionnaire (“…think about the time when 
you were working…”) although some respondents might 
have needed an option for reporting presenteeism in some 
days only, with the consequence of our estimates being 
in the upper end. Length refers to whether an episode of 
  presenteeism affects the whole working day or some hours 
only. In this study, this was build in from the fixed parameter 
of 0.27 adapted from Pauly et al19 which we believe is a more 
valid path than attempting to handle it stochastically because 
such level of detail (whether impairments occur during 3 or 
4 hours, say) would be complex to translate into effects on 
productivity. The third variable of efficiency refers to the 
effect of a worker’s impairment on the firm’s production 
(societal production). Although the two former variables are 
best assessed using workers as study units, efficiency requires 
managers or employers as study units. For that reason, this 
work adapted an impact weight from a study in more than 
800 employers of various industries19 with the advantage of 
capturing both effects on colleague workers’ productivity, as 
well as the monetary translation of it.
Limitations
This work attempted quantification of a construct for 
which no agreed-upon standard for assessment exists. The 
  validated HLQ was applied for the measurement of a worker’s 
on-the-job impairments although it has been   demonstrated 
that alternative instruments could lead to different results.26 
The translation of the measured impairments into   productivity 
effects was based on a fixed weight from an external study, 
and the validity of such approach obviously relies on the 
external population (defined by chronic health problems) 
being representative for RA patients.
The use of a multiplier and the fact that a multiplier   cannot 
be lower than one has been subject to criticism.   Relating 
to absenteeism it has been suggested that workers often 
  compensate for short-term absence during normal working 
hours.27 It is uncertain whether such compensation mecha-
nisms lower productivity loss due to presenteeism too.
Conclusion
The implication of the present study should be a strengthened 
motivation for empirical focus and methodological develop-
ments in the measurement and valuation of presenteeism. For 
example, in a typical economic evaluation setup of assess-
ing the value of a novel (and expensive) treatment regimen, 
that turns out effective in relation to functional ability, and 
thus in reducing the negative effects of presenteeism, the 
additional cost of such regimen could be outweighed by the 
saved costs of presenteeism. A second implication should be 
a critical stand in relation to the cost-of-illness literature in 
RA, which represents minimum estimates when not including 
the costs of presenteeism (and additional adjustment using a 
multiplier approach).
In conclusion, the value of lost production due to RA 
could be subject to an almost factor 2 increase if produc-
tivity effects of presenteeism and general multipliers are 
included. Results, however, remain uncertain until a sound 
methodological foundation for measuring presenteeism has 
been established.
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